These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31540935)

  • 1. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
    Braaten TJ; Brahmer JR; Forde PM; Le D; Lipson EJ; Naidoo J; Schollenberger M; Zheng L; Bingham CO; Shah AA; Cappelli LC
    Ann Rheum Dis; 2020 Mar; 79(3):332-338. PubMed ID: 31540935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
    Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
    Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.
    Subedi A; Williams SG; Yao L; Maharjan S; Strauss J; Sharon E; Thomas A; Apolo AB; Gourh P; Hasni SA; Gulley JL; Kaplan MJ; Katz JD; Gupta S
    JAMA Netw Open; 2020 Feb; 3(2):e200032. PubMed ID: 32101306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis.
    Cappelli LC; Kamal O; Jones M; Bingham CO; Shah AA
    Rheumatology (Oxford); 2024 May; 63(6):1518-1522. PubMed ID: 37647635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach.
    Tran SD; Lin J; Galvez C; Rasmussen LV; Pacheco J; Perottino GM; Rahbari KJ; Miller CD; John JD; Theros J; Vogel K; Dinh PV; Malik S; Ramzan U; Tegtmeyer K; Mohindra N; Johnson JL; Luo Y; Kho A; Sosman J; Walunas TL
    Front Immunol; 2024; 15():1331959. PubMed ID: 38558818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
    Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
    Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
    Ladouceur A; Barnetche T; Mouterde G; Tison A; Bitoun S; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Zysman M; Veillon R; Domblides C; Daste A; Gross-Goupil M; Sionneau B; Lefort F; Larroquette M; Richez C; Truchetet ME; Schaeverbeke T; Kostine M
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Increase of Circulating Transitional B Cells and Autoantibodies to Joint-Related Proteins in Patients With Metastatic Melanoma Developing Checkpoint Inhibitor-Induced Inflammatory Arthritis.
    Gatto M; Bjursten S; Jonsson CA; Agelii ML; Jonell C; McGrath S; Lönnblom E; Sareila O; Holmdahl R; Rudin A; Levin M; Gjertsson I
    Arthritis Rheumatol; 2023 May; 75(5):856-863. PubMed ID: 36409578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding.
    Daoussis D; Kraniotis P; Filippopoulou A; Argiriadi R; Theodoraki S; Makatsoris T; Koutras A; Kehagias I; Papachristou DJ; Solomou A; Kalofonos H; Liossis SN
    Rheumatology (Oxford); 2020 May; 59(5):1041-1050. PubMed ID: 32344435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study.
    Bass AR; Xie F; Jannat-Khah D; Ghosh N; Chan KK; Saxena A; Curtis JR
    Rheumatology (Oxford); 2024 Jun; ():. PubMed ID: 38889288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
    Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
    Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
    Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.
    Roberts J; Smylie M; Walker J; Basappa NS; Chu Q; Kolinsky M; Lyddell C; Ye C
    Clin Rheumatol; 2019 May; 38(5):1513-1519. PubMed ID: 30701346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review.
    Ghosh N; Jivanelli B; Couette N; Singh N; Kostine M; Simon Meara A; Liew DFL
    Rheum Dis Clin North Am; 2024 May; 50(2):325-335. PubMed ID: 38670730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy.
    Jensen AK; Chatzidionysiou K; Torp CK; Sørensen AS; Tenstad HB; Schäfer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
    Biomed Pharmacother; 2022 Apr; 148():112687. PubMed ID: 35228067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.